[1]贾 茹,魏世杰,陈文华,等.艾司奥美拉唑对大鼠肠道菌群结构组成的影响[J].肠外与肠内营养杂志,2023,(06):375-380.[doi:DOI : 10.16151/j.1007-810x.2023.06.010]
　JIA Ru,WEI Shi-jie,CHEN Wen-hua,et al.Effect of esomeprazole on intestinal microbiota structure and composition in rats[J].PARENTERAL & ENTERAL NUTRITION,2023,(06):375-380.[doi:DOI : 10.16151/j.1007-810x.2023.06.010]
点击复制

艾司奥美拉唑对大鼠肠道菌群结构组成的影响()
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2023年06期
页码:
375-380
栏目:
论著
出版日期:
2023-12-10

文章信息/Info

Title:
Effect of esomeprazole on intestinal microbiota structure and composition in rats
作者:
贾 茹; 魏世杰; 陈文华; 贺少龙; 付 岩
宁夏医科大学总医院药剂科，宁夏银川 750004
Author(s):
JIA Ru;  WEI Shi-jie;  CHEN Wen-hua;  HE Shao-long;  FU Yan
Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia China
关键词:
艾司奥美拉唑 ; 肠道菌群 ; 微生物 ; 16SrRNA测序
Keywords:
Esomeprazole;  Intestinal microbiota;  microorganism; 16S rRNA sequencing
分类号:
R574
DOI:
DOI : 10.16151/j.1007-810x.2023.06.010
文献标志码:
A
摘要:
目的：研究艾司奥美拉唑（EMZ）对肠道菌群结构和组成的影响。 方法：将 7只大鼠置于代谢笼中饲养，灌胃 EMZ（3.6 mg/kg体质量），每日 1次，连续灌胃 14 d。分别在 EMZ给药前及给药后两周收集大鼠新鲜粪便，应用 16SrRNA高通量测序，确定粪便细菌组成。 结果：EMZ灌胃两周后大鼠肠道菌群组成发生明显改变，肠单胞菌属（Intestinimonas）、嗅杆菌属（Odoribacter）和卵形拟杆菌（Bacteroides-ovatus）相对丰度较给药前明显升高（P < 0.05）；与此相反，米氏链球菌（Streptococcus_merionis）、萨特氏科（Sutterellaceae）、副拟杆菌属（Parasutterella）、假黄酮素属（Pseudoflavonifractor）、醋酐菌属（Acetanaerobacterium）、瘤胃球杆菌（Rumenbacterium）和厚壁杆菌属（Firmicutes_bacterium），给药两周后相对丰度较给药前明显降低（P < 0.05）。在科水平，给药两周后瘤胃球菌科细菌相对丰度明显低于给药前（P < 0.05）。EMZ给药后肠道细菌多样性和丰富度均较给药有所降低，但无显著性差异（P > 0.05）。 结论：EMZ处理可导致肠道菌群组成变化，对肠道菌群多样性无明显影响。使用 EMZ两周会引起一些肠道共生菌相对丰度改变，如瘤胃球菌等相对丰度降低，可能导致肠道细菌感染的风险增加。
Abstract:
Objective: This study aims to investigate the effects of esomeprazole（EMZ）on the gut microbiota structure and composition in rats. Methods: Seven rats were administered intragastrically with EMZ（3.6mg·kg-1·d-1） for 14 days. The fecal samples were freshly collected from the rats before and after EMZ administration, respectively.DNA was extracted from the fecal samples, and 16SrRNA amplicons were obtained and sequenced through the highthroughput sequencing plate (NovaSeq 6000). Results: The gut microbiota was significantly altered at 14 days post EMZ administration. The relative abundance in Intestinimonas, Odoribacter, and Bacteroides-ovatus in the fecal microbiota was dramatically enhanced at 14 days compared with those of the pre-treatment (P < 0.05). By contrast, the relative abundance of some bacterial taxons, such as Streptococcus_merionis, Sutterellaceae, Parasutterella,Pseudoflavonifractor, Acetanaerobacterium, Rumen_bacterium and Firmicutes_bacterium, was remarkably reduced at 14days (P < 0.05, vs. pre-treatment). At 14 days pos tadministration, he relative abundance of the class Ruminococcaceaewas significantly reduced compared that of pre-treatment (P < 0.05). Tthe richness and diversity of the intestinalmicrobiota showed slight reductions, while no significant differences were seen between pre- and post treatment（P >0.05）. Conclusions: EMZ administration could lead to significant changes in the microbiota composition, but not inthe alpha-diversity. Administration of EMZ for 2 weeks could induce alterations in the relative abundance of somecertain bacteria, such as Ruminococcus, which may cause increased risk in intestinal infection.

参考文献/References:


[1] 中华人民共和国国家卫生健康委员会 . 质子泵抑制剂临床应用指导原则（2020年版）（. 2020-12-03）[2020-12-08].
[2] Naito Y, Kashiwagi K, Takagi T, et al. Intestinal DysbiosisSecondary to Proton-Pump Inhibitor Use. Digestion, 2018, 97(2):195-204.
[3] 朱兰平, 赵经文, 陈 鑫, 等 . PPIs 使用与 NSAIDs 相关小肠损伤:如何平衡风险和获益 . 世界华人消化杂志, 2018,26(22):1334-1339.
[4] Elias E, Targownik LE. The Clinician’s Guide to Proton PumpInhibitor Related Adverse Events. Drugs, 2019, 79(7):715-731.
[5] 杨 曼 . 抑酸药物升高胆石症发病风险的流行病学研究及机制探讨 . 兰州大学,2022.
[6] 黄继汉, 黄晓晖, 陈志扬, 等 . 药理试验中动物间和动物与人体间的等效剂量换 . 中国临床药理学与治疗学, 2004, 9(9):1069-1072.
[7] 唐玉秀, 韦 瑶, 金 钧 .肠-肺轴以及粪菌移植在脓毒症中的作用 . 肠外与肠内营养,2023,30(3):179-184.
[8] Lombardo L, Foti M, Ruggia O, et al. Increased incidence ofsmall intestinal bacterial overgrowth during proton pumpinhibitor therapy. Clin Gastroenterol Hepatol, 2010,8(6):504-508.
[9] Lo WW, Chan WW. Proton pump inhibitor use and the risk ofsmall intestinal bacterial overgrowth: a meta-analysis. ClinGastroenterol Hepatol,2013,11(5): 483-490.
[10] Bavishi C, Dupont HL. Systematic review: the use of protonpump inhibitors and increased susceptibility to enteric infection.Aliment Pharmacol Ther, 2011,34(11-12): 1269-1281.
[11] Su T, Lai S, Lee A, et al. Meta-analysis: proton pump inhibitorsmoderately increase the risk of small intestinal bacterialovergrowth.J Gastroenterol,2018,53(1):27-36.
[12] 王晨阳, 唐 春, 赵晓璠, 等 . 抑制胃酸对大鼠空肠菌群结构和组成的影响 . 肠外与肠内营养, 2017, 24(1):46-51.
[13] Weitsman S, Celly S, Leite G, et al. Effects of Proton PumpInhibitors on the Small Bowel and Stool Microbiomes. Dig DisSci, 2022,67(1):224-232.
[14] Shin CM, Kim N, Kim YS, et al. Impact of Long-Term ProtonPump Inhibitor Therapy on Gut Microbiota in F344 Rats: PilotStudy. Gut Liver,2016,10(6):896-901.
[15] Freedberg DE, Toussaint NC, Chen SP, et al. Proton PumpInhibitors Alter Specific Taxa in the Human GastrointestinalMicrobiome: A Crossover Trial. Gastroenterology, 2015, 149(4):883-885.
[16] Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitorsaffect the gut microbiome. Gut, 2016,65(5):740-748.
[17] Bruno G, Zaccari P, Rocco G, et al. Proton pump inhibitors anddysbiosis: Current knowledge and aspects to be clarified. World JGastroenterol, 2019, 25(22):2706-2719.
[18] Wallace JL, Stephanie, et al. Proton pump inhibitors exacerbateNSAID-induced small intestinal injury by inducing dysbiosis.Gastroenterology, 2011,141(4): 1314-1322.
[19] Uejima M, Kinouchi T, Kataoka K, et al. Role of intestinalbacteria in ileal ulcer formation in rats treated with a nonsteroidalantiinflammatory drug. Microbiol Immunol, 1996, 40(8):553-560.
[20] Parkes GC, Brostoff J, Whelan K, et al. Gastrointestinalmicrobiota in irritable bowel syndrome: their role in itspathogenesis and treatment. Am J Gastroenterol, 2008, 103(6):1557-1567.

相似文献/References:

[1]方 淼.膳食纤维之于肿瘤：诱发还是预防[J].肠外与肠内营养杂志,2019,(01):24.[doi:10.16151/j.1007-810x.2019.01.011]
[2]罗 绰,等.肠道菌群与结直肠癌研究进展[J].肠外与肠内营养杂志,2019,(06):377.[doi:10.16151/j.1007-810x.2019.06.013]
　LUO Chuo,HUANG Ming-jun,WANG Yi-lin,et al.Advances in relation of intestinal flora and colorectal cancer[J].PARENTERAL & ENTERAL NUTRITION,2019,(06):377.[doi:10.16151/j.1007-810x.2019.06.013]
[3]司原成,任晨晨,康朝霞,等.肠道短链脂肪酸与单纯性肥胖症形成的关系及其机制[J].肠外与肠内营养杂志,2022,(02):121.[doi:DOI : 10.16151/j.1007-810x.2022.02.012]
　SI Yuan-cheng,REN Chen-chen,KANG Zhao-xia,et al.The formation relationship and mechanism between intestinal short chain fatty acids and simple obesity[J].PARENTERAL & ENTERAL NUTRITION,2022,(06):121.[doi:DOI : 10.16151/j.1007-810x.2022.02.012]
[4]尹天翊,郝占西,王国盼,等.益生元改善慢性代谢性疾病的研究进展[J].肠外与肠内营养杂志,2022,(04):237.[doi:10.16151/j.1007-810x.2022.04.008]
　YIN Tian-yi,HAO Zhan-xi,WANG Guo-pan,et al.Research progress of prebiotics in improving chronic metabolic diseases[J].PARENTERAL & ENTERAL NUTRITION,2022,(06):237.[doi:10.16151/j.1007-810x.2022.04.008]
[5]吴冰悦,赵武杰,贾漪涛.后生元的临床应用价值及前景展望[J].肠外与肠内营养杂志,2022,(04):242.[doi:10.16151/j.1007-810x.2022.04.009]
　WU Bing-yue,ZHAO Wu-jie,JIA Yi-tao.The clinical application value and prospect of postbiotics[J].PARENTERAL & ENTERAL NUTRITION,2022,(06):242.[doi:10.16151/j.1007-810x.2022.04.009]
[6]唐玉秀,韦 瑶,金 钧.肠-肺轴以及粪菌移植在脓毒症中的作用[J].肠外与肠内营养杂志,2023,(03):179.[doi:10.16151/j.1007-810x.2023.03.010]
　TANG Yu-xiu,WEI Yao,JIN Jun.Function of gut-lung axis and fecal bacteria transplantation in sepsis[J].PARENTERAL & ENTERAL NUTRITION,2023,(06):179.[doi:10.16151/j.1007-810x.2023.03.010]
[7]石培洁,冯 健,胡 健,等.基于“肠-肌轴”的营养干预在 ICU 获得性衰弱治疗的研究进展[J].肠外与肠内营养杂志,2023,(04):249.[doi:DOI : 10.16151/j.1007-810x.2023.04.010]
　SHI Pei-jie,FENG Jian,HU Jian,et al.Progress of nutritional interventions based on the "gut-muscle axis" inthe treatment of acquired weakness in the ICU[J].PARENTERAL & ENTERAL NUTRITION,2023,(06):249.[doi:DOI : 10.16151/j.1007-810x.2023.04.010]

备注/Memo

备注/Memo:
基金项目 ：宁夏自然科学基金（2019AAC03244）作者简介 ：贾 茹，主管药师，医学硕士，主要从事临床药学工作。E-mail：ifjia@163.com共同第一作者 ：魏世杰，主任药师，医学硕士，主要从事临床药理学工作。E-mail：nxwsj1978@163.com通讯作者 ：付 岩，E-mail：fylouisa1989@163.com
更新日期/Last Update: 1900-01-01